Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04979520 · ClinicalTrials.gov registry record · Early Phase 1
Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa
A Early Phase 1 study, sponsored by Rockefeller University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 4
- Enrollment target
NCT04979520 is a Early Phase 1 study that has completed, run by Rockefeller University. The registered enrollment target is 4 participants.
The verdict
NCT04979520, a Early Phase 1 study, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
Hidradenitis suppurativa is a disease involving skin folds, causing swelling of the skin and surrounding tissues, pain, and foul-smelling discharges. Effective treatment options are lacking. Recently, clinical trials conducted in our lab found Brodalumab was an effective drug for this disease. Weekly dosing achieved superior therapeutic outcomes compared to a dosing given once in every other week. Brodalumab was safe in both regimens, but blood and tissue studies to better understand this response are still needed. By performing this small pilot study and collecting blood and tissue samples from participants treated with Brodalumab once weekly we would like to better characterize the molecular response to this treatment, identify blood and tissue markers reflecting disease severity, and better understand disease mechanisms.
Interventions
- DRUG Brodalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-08-05 |
| Est. Completion | 2022-07-25 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04979520
The ClinicalTrials.gov registry entry for NCT04979520 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brodalumab is the first listed.
NCT04979520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04979520 about?
NCT04979520 is a clinical study titled "Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa". Hidradenitis suppurativa is a disease involving skin folds, causing swelling of the skin and surrounding tissues, pain, and foul-smelling discharges. Effective treatment options are lacking. Recently, clinical trials conducted in our lab found Brodalumab was an effective drug for this disease. Weekl...
What is the current status of trial NCT04979520?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 4 participants. The study started on 2021-08-05. Estimated completion is 2022-07-25.
What interventions are being tested in trial NCT04979520?
The interventions under investigation include: Brodalumab (DRUG).
Who is sponsoring clinical trial NCT04979520?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.